State Street
ARCT icon

State Street’s Arcturus Therapeutics ARCT Stock Holding History

State Street’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.83M Buy
569,598
+25,735
+5% +$203K ﹤0.01% 3131
2026
Q1 		$4.2M Sell
543,863
-20,403
-4% -$149K ﹤0.01% 3031
2025
Q4 		$3.46M Sell
564,266
-481,415
-46% -$5.2M ﹤0.01% 3140
2025
Q3 		$19.3M Buy
1,045,681
+25,907
+3% +$416K ﹤0.01% 2276
2025
Q2 		$13.3M Sell
1,019,774
-260,677
-20% -$3.08M ﹤0.01% 2425
2025
Q1 		$13.6M Sell
1,280,451
-45,707
-3% -$726K ﹤0.01% 2338
2024
Q4 		$22.5M Sell
1,326,158
-146,797
-10% -$2.76M ﹤0.01% 2165
2024
Q3 		$34.2M Sell
1,472,955
-50,883
-3% -$1.09M ﹤0.01% 1894
2024
Q2 		$37.1M Sell
1,523,838
-436,098
-22% -$13.2M ﹤0.01% 1815
2024
Q1 		$66.2M Buy
1,959,936
+330,270
+20% +$11.7M ﹤0.01% 1564
2023
Q4 		$51.4M Sell
1,629,666
-38,259
-2% -$909K ﹤0.01% 1691
2023
Q3 		$42.6M Sell
1,667,925
-316,243
-16% -$9.74M ﹤0.01% 1718
2023
Q2 		$56.9M Sell
1,984,168
-253,831
-11% -$6.91M ﹤0.01% 1590
2023
Q1 		$53.6M Sell
2,237,999
-19,847
-0.9% -$356K ﹤0.01% 1616
2022
Q4 		$38.3M Sell
2,257,846
-472,616
-17% -$8.24M ﹤0.01% 1821
2022
Q3 		$40.5M Sell
2,730,462
-76,456
-3% -$1.28M ﹤0.01% 1752
2022
Q2 		$44.2M Sell
2,806,918
-411,039
-13% -$8.07M ﹤0.01% 1732
2022
Q1 		$86.8M Buy
3,217,957
+1,161,883
+57% +$29.6M ﹤0.01% 1393
2021
Q4 		$76.1M Buy
2,056,074
+585,733
+40% +$23.9M ﹤0.01% 1518
2021
Q3 		$70.3M Sell
1,470,341
-285,313
-16% -$12.8M ﹤0.01% 1548
2021
Q2 		$59.4M Buy
1,755,654
+357,619
+26% +$12.1M ﹤0.01% 1718
2021
Q1 		$57.7M Buy
1,398,035
+386,116
+38% +$23M ﹤0.01% 1633
2020
Q4 		$43.9M Sell
1,011,919
-548,335
-35% -$37.1M ﹤0.01% 1719
2020
Q3 		$66.9M Buy
1,560,254
+1,302,232
+505% +$64.6M ﹤0.01% 1239
2020
Q2 		$12.1M Buy
+258,022
New +$8.89M ﹤0.01% 2317

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street's ARCT Position: Q2 2026 in Review

State Street increased its Arcturus Therapeutics (ARCT) stake by 4.7% in Q2 2026, buying an estimated $203K and bringing the position to 569,598 shares worth $3.83M. The position accounts for ﹤0.01% of the portfolio, ranked #3131.

State Street first reported a position in ARCT in Q2 2020 and has held it in 25 quarters since. The position peaked at $86.8M in Q1 2022. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • State Street held 569,598 shares of Arcturus Therapeutics worth $3.83M as of Q2 2026.
  • State Street bought 25,735 Arcturus Therapeutics shares in Q2 2026, an estimated $203K.
  • Arcturus Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3131 holding.
  • State Street first reported a position in Arcturus Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • State Street's Arcturus Therapeutics position peaked at $86.8M in Q1 2022.
  • 135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.